Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION (Tables)

STOCK-BASED COMPENSATION (Tables)

3 Months Ended

Mar. 31, 2021

STOCK-BASED COMPENSATION

Schedule of Accounting for Stock-Based Compensation

The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock option:


		Three Months Ended
		March 31,
		2021			2020

Employee and director stock option grants:
Research and development		$	29,395		$	23,735
General and administrative			95,169			120,411
Total stock-based compensation		$	124,564		$	144,146

Schedule of Stock Options Activity

A summary of stock option activity is as follows:


							Weighted
		Number of					Average
		Shares Issuable					Remaining
		Upon Exercise		Weighted			Contracted		Aggregate
		of Outstanding		Average			Term in		Intrinsic
		Options		Exercise Price			Years		Value
Outstanding at December 31, 2020		1,184,464		$	4.34				$	316,688
Granted		208,500		$	1.78
Outstanding at March 31, 2021		1,392,964		$	3.96		8.56		$	122,700

Exercisable, March 31, 2021		549,134		$	7.32		7.63		$	1,100
Unvested, March 31, 2021		843,830		$	1.77		9.17		$	121,600

Schedule of Restricted Stock Grants

The following table summarizes the restricted stock grants:


				Weighted
				Average
				Grant Date			Total Grant
		Number of		Fair Value			Date Fair
		Shares		Per Share			Value
Outstanding at December 31, 2019		9,334		$	21.00		$	196,000
Vested		(9,334)		$	21.00		$	(196,000)
Outstanding at December 31, 2020		—		$	—		$	—